Tag - NIH

SCIMap: View Impact of Federal Health Research Cuts

‘All of Us’ Research Program Identifies 275 Million New Genetic Variants

TLDR; The Value of Drugs for Rare Disease Indications May Be Higher Than You Think – Assets for Neurodevelopmental Disorders Alone May Be Worth Beyond USD $420B.

2023: Ozempic, 2nd Biggest Bank Collapse, AlphaFold, FDA Approval of Gene Therapy and CRISPR Gene Editing,….

New, Precise, and Efficient DNA Sequencing Method May Lead to Easier Testing and Earlier Cancer Detection

The Cheap Genome Is Not Enough – We Need an “Accurate and Good Genome”

Enlightenbio Releases New Report – Database of Biomarkers Curated from US Oncology Trials

Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease

Color announces Series E financing, at a valuation of $4.6 billion, to accelerate expansion of accessible and equitable public health infrastructure

Enabling Precision Medicine: Life (Sciences) in 2030

Scientific Integrity: A Coincidental Encounter

Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions

The Promise and Hope of RNA-based vaccines for COVID-19

Helix Receives FDA Emergency Use Authorization for the HelixⓇ COVID-19 NGS Test, One of the First Sequencing-Based COVID-19 Tests

Life of a Clinical Geneticist: Dealing Often With Heartless Bureaucracy

COVID-19 / SARS-CoV-2

Copyright © 2025. enlighenbio LLC. All rights reserved.